ClinicalTrials.gg
RecruitingNCT05335070Updated Dec 5, 2025

Reducing Pain From Wisdom Molar Extractions

A Phase 2 interventional study of Temporo-masseteric Nerve Block in Acute Pain, sponsored by Rutgers, The State University of New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Rutgers, The State University of New Jersey · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.

Planned enrollment
265th of 322
20 · median 86
Started
2022
with 21 others
Phase 2
56 of 353
8 open now
Primary completion
2026-11
later than 12 of 54 live
Registered
259th of 353
by date

Among the 353 studies in Acute Pain with a site in United States, this one is the 265th largest by planned enrollment of the 322 interventional ones that give a count, is one of 22 that started in 2022, is one of 56 in phase 2, reaches primary completion later than 12 of the 54 other live ones, and was the 259th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

This is a pilot study evaluating the ability of the Temporo-masseteric Nerve Block local anesthetic injection (this was called the Twin Block earlier) to reduce pain experienced by individuals undergoing removal of lower third molar(s) under intravenous sedation. Study participants will be queried for pain experience and pain medications taken during the first post-operative week and will present for a follow-up visit on Day 8.

Read the detailed description

Each year, over 3.5 million, mostly, healthy young adults, have their third molar teeth ('wisdom teeth') removed under sedation and are often given opioid prescriptions for managing their pain. Wisdom molar removal is one of the most common reasons for opioid prescriptions to be given to adolescents. There is a national thrust to reduce both the dose and the duration of such opioid prescriptions because even short-term opioid exposures increase risk for narcotic addiction and misuse. Non-opioid options to manage pain will still allow for sufficient pain control without risking addiction, and hence, a fundamental component of our response to combat the current national opioid crisis.

The investigators are going to study a promising option- the Temporo-masseteric Nerve Block (TMNB) dental anesthetic injection (This was called the Twin Block earlier). The TMNB involves injecting the standard dental numbing medication in a way that 'numbs' the 'jaw-clencher' muscles on the side of the face. The investigators found that the TMNB relieved jaw pain stemming from these muscles, in a quick and sustained manner, even in patients whose pain following wisdom tooth removal primarily came from 'taut' and tender jaw-clencher muscles.

In this pilot study, the investigators will deliver the Temporo-masseteric Nerve Block (TMNB) injection to 20 individuals (study participants) who undergo extraction of at least 1 lower wisdom molar dental extraction under intravenous sedation, on the side/s of lower molar removal at the end of the procedure. The participant's pain experience, medications taken for pain, as well as any adverse effects from either pain medications or the TMNB injection will be queried for a period of 1 week following the procedure (remotely). On Day 8 (one week after the procedure), the participants will return for a follow-up visit. The participants' pain experience will be compared with historical controls. This study can support a simple, safe and inexpensive means to reduce pain after a common procedure and will provide proof-of-concept for the potential non-opioid analgesic role of TMNB injection following wisdom molar removal.

The participant will be advised to take a combination of ibuprofen and acetaminophen (600 mg ibuprofen and 325 mg acetaminophen) every 4-6 hours for pain, unless it is mild, for which OTC strength analgesics would prove adequate (ibuprofen or acetaminophen). 5/300 mg hydrocodone with acetaminophen will be utilized for pain management if the patient's pain does not respond to 600 mg ibuprofen and 325 mg acetaminophen, even an hour after medication.

The key outcomes collected will include peak-pain by 4 hours post-procedure (measured using numerical pain rating scale score NRS, from 0-10, with 0 corresponding to no pain, 1-3 corresponding to mild, 4-6 to moderate and 7-10 to severe pain), passive mouth opening, masticatory muscle pain to palpation (masseter and temporalis muscles), total dosage of pain medication/s consumed. Adverse effects to pain medication consumption (nausea/ drowsiness/ gastritis etc) or to the TMNB injection will also be recorded. Daily pain experience will be recorded each of the 7 days post-operatively either as a survey emailed to the participant or queried over the phone by research personnel.

A week after the procedure, the participant will present for a post-operative evaluation. The extraction/s site/s will be evaluated for any infection/delayed healing.

03

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • Temporo-masseteric Nerve Block
  • Twin Block
  • Prescription opioids
  • Acute Post-extraction pain
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years of age or older (up to 64 years)
  • Any demographic
  • ASA 1 and 2 (mild or absent systemic illnesses, deemed fit for undergoing dental extractions under intravenous sedation)
  • Not pregnant (as will not qualify to undergo procedure under intravenous sedation as part of routine standard-of-care)
  • Adequate mental ability to understand and provide
  • Has smart phone and internet connection

Exclusion criteria

Exclusion Criteria:

  • Age older than 64 years (because they are poor candidates for undergoing procedures under intravenous sedation)
  • Pregnant
  • Incapable of providing
  • Any systemic condition that renders the patient at higher risk for complications under intravenous sedation
  • Documented allergy to the dental local anesthetic
  • Inability to tolerate any of the commonly used pain medications such as combination opioids, acetaminophen (Tylenol®) or ibuprofen (Motrin® or Advil®)
  • Limitation in adequate mouth opening in presence/absence of pain
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Temporo-masseteric Nerve Block (TMNB) Injection with Local Anesthetic

    Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine, on the side/s of lower wisdom molar extraction/s

    Drug: Temporo-masseteric Nerve Block

Interventions

  • DrugTemporo-masseteric Nerve Block

    Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s

06

What researchers measure

Primary outcomes

  1. Peak post-operative Pain Score

    Every 30 minutes, the patient's pain score (Numerical Pain Rating Scale with scores from 0-10, (the NRS scale), with 0= no pain, 1-3= mild pain, 4-6= moderate pain, 7-10= severe pain) will be recorded to document peak pain score by hour 4. If the patient were to report a score from 7-10 at any time, no additional delay/pain score enquiry will take place and the patient will be directed to take the first dose of post-operative pain medication as described elsewhere.

    Time frame: up to 4 hours on day of procedure, post-procedure

  2. Mean Numerical Pain Rating Scale pain score

    The average pain score reported by the patient during the entire post-operative week will be assessed

    Time frame: One week

  3. Passive Mouth opening

    Passive mouth opening will be measured (in mm) at baseline, post-procedure before as well as 15 min after TMNB injection and finally, during the post-operative visit (Day 8) will be measured

    Time frame: Baseline, post-procedure (Day 1) and at post-operative visit (Day 8)

  4. Masticatory muscle pain to palpation- Temporalis and Masseter

    Numerical pain rating scale pain scores reported by the patient upon palpation of the masseter and temporalis muscles will be recorded at baseline, post-procedure (before and 15 min after TMNB injection) and at the post-operative visit one week after procedure

    Time frame: Baseline, post-procedure (Day 1) and at post-operative visit (Day 8)

  5. Total dose of pain medication- acetaminophen, ibuprofen and hydrocodone

    Total dose of pain medications consumed over the first post-operative week, for each of the medications will be recorded in mg

    Time frame: 8 Days

  6. Adverse effects

    The patient will be queried each day for any adverse effects from pain medications and any adverse effects at the site of injection (infection, pain etc)

    Time frame: 8 days

07

Study locations

1 of 1 sites recruiting
  • The University Hospital- Dental Clinic
    Newark, New Jersey 07103, United States
    Recruiting
08

References and documents

Publications

  • Quek SYP, Gomes-Zagury J, Subramanian G. Twin Block in Myogenous Orofacial Pain: Applied Anatomy, Technique Update, and Safety. Anesth Prog. 2020 Jun 1;67(2):103-106. doi: 10.2344/anpr-67-01-03. PubMed 32633773 ↗
  • Kanti V, Ananthan S, Subramanian G, Quek SYP. Efficacy of the twin block, a peripheral nerve block for the management of chronic masticatory myofascial pain: A case series. Quintessence Int. 2017 Oct 6:725-729. doi: 10.3290/j.qi.a39094. Online ahead of print. PubMed 28990015 ↗
  • Quek S, Young A, Subramanian G. The twin block: a simple technique to block both the masseteric and the anterior deep temporal nerves with one anesthetic injection. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Sep;118(3):e65-7. doi: 10.1016/j.oooo.2014.01.227. Epub 2014 Feb 6. PubMed 24703404 ↗

Individual participant data

Plan to share: Yes — After anonymizing, IPD will be shared after the study is completed.

Supporting information: Study protocol

Time frame: After study completion, upon review of request

Access criteria: A written request will be evaluated and responded to.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 50 months after the start.

Of 41 phase 2 interventional studies under Acute Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2022
First posted
Apr 19, 2022
StartActual
Sep 13, 2022
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05335070
Responsible party
Gayathri Subramanian (Associate Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Apr 19, 2022
Start date
Sep 13, 2022
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 5, 2025

Study contacts

Gayathri Subramanian, PhD, DMD
Contact
subramga@sdm.rutgers.edu
9739723418
Samuel YP Quek, DMD, MPH
Contact
732 570 1996
Gayathri D Subramanian, PhD, DMD
principal investigator · Rutgers School of Dental Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion